drugset / Trial / NCT05505292
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
Phase 4
Completed
32 enrolled
State University of New York College of Optometry
Bausch & Lomb Incorporated · collabNovartis Pharmaceuticals · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a prospective, single site, randomized, double masked, comparator-controlled study designed to evaluate the efficacy of lifitegrast ophthalmic solution 5% in treating the symptoms of dry eye in soft contact lens wearers as compared to control. We hypothesize that there will be a significant improvement in dry eye symptoms in contact lens wearers using lifitegrast as compared to those being treated with control (lifitegrast vehicle).
Timeline
- Start
- 2022-09-22
- Primary completion
- 2023-05-15
- Completion
- 2023-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lifitegrast | Unknown | 5 % | — |